Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
  • Ahn, Myung-Ju
  • Han, Ji-Youn
  • Kim, Sang-We
  • Lee, Ki Hyeong
  • Kim, Dong-Wan
  • ... Lee, Gyeong-won
  • 외 14명
Citations

WEB OF SCIENCE

3

키워드

LazertinibT790M3rd generation EGFR TKI
제목
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
저자
Ahn, Myung-JuHan, Ji-YounKim, Sang-WeLee, Ki HyeongKim, Dong-WanLee, Yun-GyooCho, Eun KyungLee, Gyeong-wonLee, Jong-SeokKim, Joo-HangKim, Jin-SooMin, Young JooLee, Sung SookShin, Sang WonKim, HyeRyunHong, Min HeeAhn, Jin SeokLee, Seoung OhKim, SoheeCho, Byoung Chul
발행일
2019-05-20
유형
Meeting Abstract
저널명
Journal of Clinical Oncology
37
15